Biomea Fusion (Biomea Fusion) Debt-to-Equity : 0.06 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Biomea Fusion Debt-to-Equity?

Biomea Fusion's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.47 Mil. Biomea Fusion's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $7.83 Mil. Biomea Fusion's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $169.24 Mil. Biomea Fusion's debt to equity for the quarter that ended in Dec. 2023 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Biomea Fusion's Debt-to-Equity or its related term are showing as below:

BMEA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.04 Max: 0.06
Current: 0.06

During the past 5 years, the highest Debt-to-Equity Ratio of Biomea Fusion was 0.06. The lowest was 0.02. And the median was 0.04.

BMEA's Debt-to-Equity is ranked better than
69.78% of 1069 companies
in the Biotechnology industry
Industry Median: 0.14 vs BMEA: 0.06

Biomea Fusion Debt-to-Equity Historical Data

The historical data trend for Biomea Fusion's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomea Fusion Debt-to-Equity Chart

Biomea Fusion Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.05

0.02

0.06

Biomea Fusion Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial												0.02	0.16	0.06	0.06	0.06

Competitive Comparison of Biomea Fusion's Debt-to-Equity

For the Biotechnology subindustry, Biomea Fusion's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomea Fusion's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomea Fusion's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Biomea Fusion's Debt-to-Equity falls into.

Biomea Fusion Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biomea Fusion's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.466	+	7.83)	/	169.237
	=	0.06

Biomea Fusion's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.466	+	7.83)	/	169.237
	=	0.06

Biomea Fusion (NAS:BMEA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Biomea Fusion Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Biomea Fusion's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomea Fusion (Biomea Fusion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomea Fusion Inc (NAS:BMEA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 Middlefield Road, 4th Floor, Redwood City, CA, USA, 94063

Website

https://www.biomeafusion.com

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

Executives

Juan Pablo Frias	officer: Chief Medical Officer	900 MIDDLEFIELD ROAD, 4TH FLOOR, C/O BIOMEA FUSION, INC., REDWOOD CITY CA 94063
A2a Pharmaceuticals, Inc.	10 percent owner	59 5TH AVE, NEW YORK NY 10003
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen	director, 10 percent owner	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Hitchcock Michael J.m.	director	C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063
Franco Valle	officer: Chief Financial Officer	999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Elizabeth Faust	director	C/O BIOMEA FUSION, INC., 900 MIDDLEFIELD RD., 4TH FL, REDWOOD CITY CA 94063
Sumita Ray	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Sotirios Stergiopoulos	director	C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063
Rainer M Erdtmann	director, 10 percent owner, officer: President and COO	1073 ARLINGTON BLVD., EL CERRITO CA 94530
Thomas Andrew Butler	director, 10 percent owner, officer: CEO	726 MAIN STREET, REDWOOD CITY CA 94065
Eric Aguiar	director	888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Biomea Health, Llc	10 percent owner	726 MAIN STREET, REDWOOD CITY CA 94063